All Episodes
eCysticFibrosis Review — 72 episodes
Cystic Fibrosis Life Transitions
CF and Diet and Nutrition: The Changing Paradigm
ETI (CFTR Triple Therapy): Clinical Opportunities
Pulmonary Exacerbations and IV Antibiotics
Race, Ethnicity, and Cystic Fibrosis
The Pancreas, Malnutrition, and CFTR Modulators
CF and COVID-19: The Data and the Real World
Managing Psychosocial and Economic Stress
Overcoming Shutdown Challenges
Maintaining CF Infection Prevention and Control
Clinical Considerations for Women with CF
Antibiotics, Dosing, and CFTR
Bringing Telemedicine to the CF Clinic: A Success Story
CFTR, Growth & Liver Disease: A Clinical Perspective
In the Clinic: Triple Combination CFTR Modulation
Addressing Mental Health in CF
Clinical Considerations: New Anti-Inflammatories & New CFTR Modulators
Continuous Alternating Therapies: A Clinical Perspective
In The Clinic: CFTR Modification & Nutritional Deficiencies
NTM Infection: Today's Treatments & New Antibiotics in Development
NTM Infection: Risk of Patient-to-Patient Transmission in CF Centers
NTM Infection: Risks of Acquisition from the Environment
Clinical Insight: CFTR Modulators
Clinical Approaches to MDR Lung Infections
Lung Transplant and CRC Screening
CFTR Modulators: Clinical Insights
Screening and Diagnosis of CFRD
New Directions in CFTR Modification
Nutritional Management for Individuals with CF: Practical Applications
Adherence – What You Should be Telling Your Patients
Weighing the Options in Managing Exacerbations
Future Landscape of CFTR Modulators
Pseudomonas aeruginosa Eradication and Outcomes: Key Questions
Nutritional Issues in Cystic Fibrosis
Trends in Inhaled Antibiotic Therapy
Pulmonary Exacerbations and the Microbiology of the CF Lung
The Current State of CFTR Modification
Breaking Coverage of CAT trial
Breaking Coverage of CAT trial
Breaking Coverage of CAT trial
Agents for the management of Pseudomonas aeruginosa infection
Benefits of CFTR Modification Beyond FEV1 Improvement
The Effects of CFTR-modifying Therapies
Optimizing Nutrition in Individuals with Cystic Fibrosis
Improving digestive capabilities in nutritionally compromised patients with CF
P. aeruginosa eradication and reinfection
Pulmonary exacerbations: diagnoses, and therapeutic regimens
What Does CFTR Tell Us About Lung Disease?
Behavioral Treatment to Improve Dietary Adherence and Weight Gain in Children with Cystic Fibrosis
Highlights of the 27th Annual North American Cystic Fibrosis Conference
Special Edition 2014 - Steven Rowe: Highlights of the 27th Annual North American Cystic Fibrosis Conference
Highlights of the 27th Annual North American Cystic Fibrosis Conference
Highlights of the 27th Annual North American Cystic Fibrosis Conference
New Therapies in Cystic Fibrosis Directed Toward the Basic Defect
P. aeruginosa Eradication
Strategies for the Improvement of Nutrition Outcomes
Adherence to Chronic Inhaled Therapies
Featured Cases: Emerging Pathogens in Cystic Fibrosis
Featured Cases: The Role of Exercise and Physical Activity in Optimizing Outcomes Among Patients with CF
Featured Cases: Interventions to Improve Nutrition in Patients with CF
Featured Cases: Modifiers of CF Lung Disease
Featured Cases: Exacerbation Therapies
Featured Cases: New Inhalation Therapies
Featured Cases: State-of-the-Art Treatment for CF Lung Disease
Featured Cases: Vitamin D and Bone Health
Featured Cases: Nutritional Challenges and Complications in Patients with CF
Featured Cases: Allergic Bronchopulmonary Aspergillosis (ABPA)
Featured Cases: Cystic Fibrosis–Related Diabetes
Measurement of Early Lung Disease in Children With Cystic Fibrosis
Emerging Pathogens in Cystic Fibrosis
How to Interpret Genetic Tests for Cystic Fibrosis